Drug Profile
ASP 8477
Alternative Names: ASP8477Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Analgesics
- Mechanism of Action Central nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 30 Dec 2015 Discontinued - Phase-I for Neuropathic pain in Japan (PO)
- 30 Oct 2015 Discontinued - Phase-I for Neuropathic pain (In volunteers) in France, Belgium (PO)
- 30 Oct 2015 Discontinued - Phase-II for Neuropathic pain in United Kingdom, Czech Republic, Poland, Germany (PO)